(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 October 2024 (24.10.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/220397 A1

(51) International Patent Classification:
A61P 35/00 (2006.01) *C07K 16/28* (2006.01)

(21) International Application Number:
PCT/US2024/024741

(22) International Filing Date:
16 April 2024 (16.04.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/459,828	17 April 2023 (17.04.2023)	US
63/463,273	01 May 2023 (01.05.2023)	US

(71) Applicant: **AMUNIX PHARMACEUTICALS, INC.** [US/US]; 2 Tower Pl #1100, South San Francisco, California 94080 (US).

(72) Inventors: **DUBROVSKAYA, Viktoriya**; c/o Amunix Pharmaceuticals, Inc., 2 Tower Pl #1100, South San Francisco, California 94080 (US). **JOHANSEN, Eric**; c/o Amunix Pharmaceuticals, Inc., 2 Tower Pl #1100, South San Francisco, California 94080 (US). **KHORSAND, Sina**; c/o Amunix Pharmaceuticals, Inc., 2 Tower Pl #1100, South San Francisco, California 94080 (US). **LIU, Lucas**; c/o Amunix Pharmaceuticals, Inc., 2 Tower Pl #1100, South San Francisco, California 94080 (US). **SCHELLENBERGER, Volker**; c/o Amunix Pharmaceuticals, Inc., 2 Tower Pl #1100, South San Francisco, California 94080 (US). **TO, Milton**; c/o Amunix Pharmaceuticals, Inc., 2 Tower Pl #1100, South San Francisco, California 94080 (US). **YOUNG, Tracy**; c/o Amunix Pharmaceuticals, Inc., 2 Tower Pl #1100, South San Francisco, California 94080 (US). **FRENZEL, André**; c/o Yumab GmbH, Inhoffenstraße 7, 38124 Braunschweig (DE). **KUHN, Philipp**; c/o Yumab GmbH, Inhoffenstraße 7, 38124 Braunschweig (DE).

(74) Agent: **VELEMA, James H.** et al.; LATHROP GPM LLP, 28 STATE STREET, Boston, Massachusetts 02109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2024/220397 A1

(54) Title: COMPOSITIONS TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS FOR MAKING AND USING THE SAME

(57) Abstract: Provided herein are, *inter alia*, antibody binding domains for cluster of differentiation 3 T cell receptor (CD3), antibody binding domains for epidermal growth factor receptor (EGFR), cleavable linker sequences, and protease-activatable bispecific fusion proteins such as protease-activatable T cell engagers, as well as uses and methods of treatment.